

## ANSWERING REVIEWERS

Jin-Lei Wang, Director  
Editorial Office  
Baishideng Publishing Group Co., Limited



**Title:** Endoglin in liver fibrogenesis-bridging basic science and clinical practice

**Revision of ESPS Manuscript no. 7485**

Dear Editor,

please find enclosed the revised version of our review entitled "*Endoglin in liver fibrogenesis - Bridging basic science and clinical practice*" by S. K. Meurer, M. Alsamman, D. Scholten and R. Weiskirchen.

The manuscript has been improved according to the suggestions of reviewers. We have adapted the draft to the Journal style, added a core tip, and made the following changes that are marked in red colour in the revised draft:

**Reviewer 00289741:** Thank you very much for the time you spent to read our review and the overall positive evaluation.

**Reviewer 00289699:** Thank you very much for the time you spent to read our review and the overall positive evaluation.

**Reviewer 00289695:** We have addressed your minor concerns as follows:

- a) Figure 1 is now mentioned more often in the text.
- b) As suggested, we have changed the sentence in page 7 to : "Endoglin, a type I transmembrane glycoprotein, is expressed....."
- c) As suggested, we have changed sEng to sol-Eng throughout the text.
- d) We have added that (i) there is presently not much knowledge how the expression of the isoforms and soluble form of endoglin is regulated in diverse liver cell subpopulations and (ii) the overall concentration of the soluble form increases during hepatic fibrogenesis.
- e) We have changed the sentences on page 5 according to your advice.
- f) We have taken out the redundancy in regard to the chromosomal localization of human Endoglin.

Please note that the copyright assignment form signed by all authors will be send *via fax* to the editorial office.

We hope that the revised version of our review is now suitable for publication in the *World Journal of Biological Chemistry*.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'R. Weiskirchen'.

Ralf Weiskirchen, Professor,  
Institute of Clinical Chemistry and Pathobiochemistry,  
RWTH University Hospital Aachen,  
Pauwelsstr 30,  
D-52074 Aachen, Germany.  
Email: rweiskirchen@ukaachen.de